Glucagon: A Checklist Guide to Its Application Scope
Title: Glucagon: A Checklist Guide to Its Application Scope Abstract: This checklist guide delineates glucagon’s application scope, emphasizing its critical role in severe hypoglycemia management and diagnostic gastrointestinal procedures. Market analysis reveals a CAGR of 6.8% (2023-2030), driven by diabetes prevalence and novel peptide formulations. Brand comparison highlights Novo Nordisk’s dominance (65% market share) versus generic biosimilars. Technical advantages include rapid glycogenolysis; limitations involve short half-life (3-6 min) and nausea. Product parameters contrast nasal powder (3 mg) vs. injectable (1 mg). The guide integrates factory GMP certifications, logistics cold-chain requirements, and selection criteria for peptide purity (>98%). Current industry trends favor stable glucagon analogs and dual-action peptides, with regulatory approvals (FDA/EMA) as core quality benchmarks.